Latest news

Debiopharm S.A. announces the purchase of all outstanding shares of H3 Pharma

Debiopharm S.A. announces marketing approval for a new formulation of Eloxatin® (Oxaliplatin for injection)

H3 Pharma receives approvable letter from FDA for Sanvar® for esophageal variceal bleeding

Debiopharm S.A. and Rowfarma S. de R.L. de C.V. enter into an Exclusive Licensing Agreement in Mexico for two approved…

Debiopharm S.A. and GPC Biotech AG Announce Partnering of Small Molecule MHC Class II Antagonists Program for Autoimune Diseases

Debiopharm S.A. and Tulane Cancer Center nominate Dr T. Curiel and Dr W. Zou, the 2004 Mauvernay Research Excellences Scholars

New Data presented on Debiopharm´s Debio-025 at the 11th International Symposium on Hepatits C virus and related viruses

Debiopharm and Watson Pharmaceuticals enter into an Exclusive Licensing Agreement for two approved urology products – Trelstar® DEPOT and Trelstar®…

H3 Pharma Inc. and DSM Biologics sign development agreement for SC-1 monoclonal antibody for the treatment of gastric cancer